Maze Therapeutics, Inc.

NasdaqGM:MAZE Stock Report

Market Cap: US$1.7b

Maze Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Maze Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-8.8%

Buyback Yield

Total Shareholder Yield-8.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Mar 27

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

Summary I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program’s success and planned pivotal trial initiation. The company maintains a strong cash position, funding operations into 2028, and has pipeline optionality with MZE782 targeting PKU and CKD in upcoming POC studies. Read the full article on Seeking Alpha
Analysis Article • Dec 15

We're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 26

Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist

Summary Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease, showing promise in preclinical studies and currently in a phase 2 trial. Financials reveal a cash runway of 6.4 quarters from September, with significant R&D and G&A expenses, and a potential price drop post-lockup period. Due to the lack of proof of concept and potential pricing pressures, I recommend avoiding investment in Maze Therapeutics for now. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MAZE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MAZE's dividend payments have been increasing.

Dividend Yield vs Market

Maze Therapeutics Dividend Yield vs Market
How does MAZE dividend yield compare to the market?
SegmentDividend Yield
Company (MAZE)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.1%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast (MAZE) (up to 3 years)n/a

Notable Dividend: Unable to evaluate MAZE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MAZE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MAZE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MAZE has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 23:39
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Maze Therapeutics, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Debjit ChattopadhyayGuggenheim Securities, LLC
Ananda GhoshH.C. Wainwright & Co.